Matters

Chris has represented and advised clients in Hatch-Waxman cases involving blockbuster drug products, including: Revlimid (lenalidomide), Pomalyst (pomalidomide), Symbicort (budesonide/formoterol), Victoza (liraglutide), Ozempic and Wegovy (semaglutide), Entresto (sacubitril/valsartan), Bendeka and Belrapzo (bendamustine), Abilify Maintena (aripiprazole), Venclexta (venetoclax), and Sprycel (dasatinib).